KR880013577A - Veterinary Drug Formulations - Google Patents

Veterinary Drug Formulations Download PDF

Info

Publication number
KR880013577A
KR880013577A KR870004721A KR870004721A KR880013577A KR 880013577 A KR880013577 A KR 880013577A KR 870004721 A KR870004721 A KR 870004721A KR 870004721 A KR870004721 A KR 870004721A KR 880013577 A KR880013577 A KR 880013577A
Authority
KR
South Korea
Prior art keywords
pharmaceutical formulation
veterinary drug
drug formulations
animal
formulation
Prior art date
Application number
KR870004721A
Other languages
Korean (ko)
Other versions
KR900000547B1 (en
Inventor
김무곤
안창돈
Original Assignee
김무곤
안창돈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김무곤, 안창돈 filed Critical 김무곤
Priority to KR1019870004721A priority Critical patent/KR900000547B1/en
Publication of KR880013577A publication Critical patent/KR880013577A/en
Application granted granted Critical
Publication of KR900000547B1 publication Critical patent/KR900000547B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient

Abstract

내용 없음No content

Description

동물용 약품제형Veterinary Drug Formulations

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (3)

기재로서 유당, 백당, 포도당, 덱스트린에서 선택된 1이상의 당류와 동물용 약품 및 1이상의 방부제 결합제를 함유한 조성물을 직경 10내지 50cm가량의 블럭형상으로 성형제조한 동물용 약품제형.An animal pharmaceutical formulation made of a composition containing one or more sugars selected from lactose, white sugar, glucose, and dextrin as a base material, and an animal medicine and one or more preservative binders in a block shape having a diameter of about 10 to 50 cm. 제1항에서 당류의 함량이 60%이상이고 제형의 강도가 10kg/cm2이상인 동물용 약품제형.The veterinary pharmaceutical formulation of claim 1, wherein the sugar content is 60% or more and the strength of the formulation is 10kg / cm 2 or more. 제1또는 제2항의 약품제형을 투여하여 가축의 질병을 예방 또는 치료하는 방법.A method for preventing or treating a disease in a livestock by administering the pharmaceutical formulation of claim 1. ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019870004721A 1987-05-14 1987-05-14 Pharmaceutical formation for using animal KR900000547B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019870004721A KR900000547B1 (en) 1987-05-14 1987-05-14 Pharmaceutical formation for using animal

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019870004721A KR900000547B1 (en) 1987-05-14 1987-05-14 Pharmaceutical formation for using animal

Publications (2)

Publication Number Publication Date
KR880013577A true KR880013577A (en) 1988-12-21
KR900000547B1 KR900000547B1 (en) 1990-01-31

Family

ID=19261396

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870004721A KR900000547B1 (en) 1987-05-14 1987-05-14 Pharmaceutical formation for using animal

Country Status (1)

Country Link
KR (1) KR900000547B1 (en)

Also Published As

Publication number Publication date
KR900000547B1 (en) 1990-01-31

Similar Documents

Publication Publication Date Title
KR880009639A (en) Sustained Release Matrix Formulations
DE69132688D1 (en) METHOD FOR TREATING AND PREVENTING TYPE-1 DIABETIS BY ORAL ADMINISTRATION OF INSULIN
SE8504945L (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ANTRACYCLING GYCOSIDES
DK0724885T3 (en) Pernasal composition and pernasal preparation containing this
NO920357D0 (en) PREPARATION FOR CONTROLLED RELEASE OF ACTIVE SUBSTANCES SUITABLE AS A THERAPEUTIC OR FOR IMPROVING THE GROWTH AND RECOVERY OF DRUGS
SE7902742L (en) DISUBSTITUTED 3-CEFEM-4-CARBOXYLIC ACID DERIVATIVES AND PROCEDURES FOR THE PREPARATION
DE58901002D1 (en) AGENT WITH DESTROYING EFFECT ON MALIGNE TUMORS, METHOD FOR THE PRODUCTION THEREOF AND PREPARATION FOR USE IN THE THERAPY OF CANCER DISEASES.
KR830002510A (en) Composition consisting of biologically active compound and hydroxyalkyl starch
ATE100095T1 (en) 2,2-DIMETHYLCHROMONE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ATE94764T1 (en) NASAL APPLICABLE MEDICATION, PROCESS FOR ITS PRODUCTION AND ITS USE.
KR950000168A (en) Semi-Solid Drugs and Manufacturing Method Thereof
DE3783923T2 (en) AN ACTIVE SUBSTANCE AND A MEDICINAL PRODUCT CONTAINING WATER SWELLING POLYMER.
KR940005283A (en) Drugs containing glycentin as active ingredient
ES2092784T3 (en) TABLET THAT ALLOWS THE ADMINISTRATION OF TABLETS TO DOMESTIC ANIMALS.
IE45054L (en) Veterinary composition
KR880013577A (en) Veterinary Drug Formulations
KR890003373A (en) Use of compounds to treat sleep disorders and depression
KR900017599A (en) Pharmaceutical composition for tumor treatment
ATE2746T1 (en) PIPERIDINE DERIVATIVES OF 4,5-DIALKYL-3-HYDROXYPYRROL-2-CARBONS[UREESTERS, THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
RU95120165A (en) DRUG IMMUNE SUBSTITUTING ACTION ON THE BASIS OF CELLULAR SUSPENSION AND METHOD FOR TREATMENT OF THE ACQUIRED IMMUNODEFICIENCY SYNDROME (HIV INFECTION) USING THIS ANTID
DK0402208T3 (en) Composition of vitamin A in physiological dose and various active ingredients with a therapeutic activity
KR880000094A (en) Gastritis Treatment
KR880002521A (en) Pharmaceutical formulation
KR920019349A (en) Use of R (+)-3-amino-1-hydroxy-pyrrolidin-2-one to treat anxiety
KR900012622A (en) Skin disease treatment composition

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19990201

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee